Corcept Therapeutics (CORT-Q) Analyst Research & Price Targets - The Globe and Mail

Earnings Estimates

	Current Qtr06/2026	Next Qtr09/2026	Fiscal Yr12/2026	Fiscal Yr12/2027
Average Estimate	$-0.04	$0.31	$0.53	$2.27
Number of Estimates	3	3	4	4
High Estimate	$0.02	$0.34	$0.80	$5.38
Low Estimate	$-0.09	$0.26	$0.28	$0.36
Prior Year	$0.29	$0.16	$0.82	$0.53
Growth Rate Est. (year over year)	-113.79%	+93.75%	-35.37%	+328.30%

Earnings History - Surprises*

	Qtr Ending03/2026	Qtr Ending12/2025	Qtr Ending09/2025	Qtr Ending06/2025
Reported	$-0.30	$0.20	$0.16	$0.29
Estimate	$-0.30	$0.27	$0.18	$0.23
Difference	unch	-0.07	-0.02	+0.06
Surprise	unch	-25.93%	-11.11%	+26.09%

* Earnings are based on GAAP income from continuing operations.

Average Analyst Ratings

3.86

3 Mths Ago7

3.67

2 Mths Ago6

4.33

1 Mth Ago6

4.43

Current7

Ratings Values:

Strong Buy5

Moderate Buy4

Hold3

Moderate Sell2

Strong Sell1

Ratings Breakdown

	3 Mths Ago	2 Mths Ago	1 Mth Ago	Current
# of Analysts:	7	6	6	7
	4	3	4	5
Holds	2	2	2	2
	1	1

Key:

Strong Buy

Moderate Buy

Hold

Moderate Sell

Strong Sell

More from The Globe

Outgoing Telus CEO presents sunny view of his tenure, despite stock price challenges

Thursday’s Insider Report: Multiple executives sell shares in this stock that’s doubled in 2026

Dye & Durham dumps CEO, Tyler Proud now leads company through board committee

number cruncher

Searching for European momentum stocks in a frothy market

Bullish potential on Intact Financial Corp.

Barlow’s Research Roundup: These stocks are the big winners from Canada’s new nuclear energy plan

Where will tech stocks go from here?

Six bargain stock picks from hedge fund managers